Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Trial Profile

Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Pazopanib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 05 Feb 2015 Planned End Date changed from 1 Jun 2014 to 1 Jun 2016 according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top